The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

INTRODUCTION: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combination in relation to chemotherapy alone in this pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, David J., Chen, Shuai, Eldredge, Joanna B., Schokrpur, Shiruyeh, Li, Debory, Quan, Zhikuan, Chan, Jason W., Cummings, Amy L., Daly, Megan E., Goldman, Jonathan W., Gubens, Matthew A., Harris, Jeremy P., Onaitis, Mark W., Zhu, Viola W., Patel, Sandip P., Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679033/
https://www.ncbi.nlm.nih.gov/pubmed/36426286
http://dx.doi.org/10.1016/j.jtocrr.2022.100427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679033/
https://www.ncbi.nlm.nih.gov/pubmed/36426286
http://dx.doi.org/10.1016/j.jtocrr.2022.100427

Ejemplares similares